FDA-Cleared, Medicare-Reimbursed, ResponseDX: Tissue of Origin(TM) Test Added to National Institute of Health's (NIH) Genetic

FDA-Cleared, Medicare-Reimbursed, ResponseDX: Tissue of Origin(TM) Test Added
to National Institute of Health's (NIH) Genetic Testing Registry

LOS ANGELES, June 12, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help guide cancer therapy selection, today announced
that the National Institutes of Health (NIH) Genetic Testing Registry (GTR), a
searchable database of genetic and genomic tests, has been updated to include
the recently introduced ResponseDX: Tissue of Origin^TM test. Response
Genetics acquired this test as part of its acquisition of the assets of the
former PathWork Diagnostics in late 2013 and introduced the test, the only
FDA-cleared test of its kind, to the market in February 2014. The GTR offers
detailed clinical and scientific information about testing options for
physicians and patients.

"We are very proud that the GTR has elected to include the ResponseDX: Tissue
of Origin^TM test, and will soon include all of our other molecular tests in
the Response Genetics portfolio", said Thomas A. Bologna, Chairman and Chief
Executive Officer of Response Genetics. "A centralized information repository
searchable by laboratory, mutation, test, etc. is a tremendous benefit to the
community of oncologists, pathologists and patients we serve.In addition to
including the basic information about the ResponseDX: Tissue of Origin^TM
test, namely that is an FDA-cleared, Medicare-reimbursed gene expression
analysis that provides a definitive diagnosis for poorly-differentiated or
metastatic cancers without a clear primary origin, the GTR also includes
detailed information about the test's development, validation and clinical
utility making this information easily accessible to physicians, researchers
and patients.

"We are very pleased to add Response Genetics' ResponseDX: Tissue of Origin^TM
test to the GTR, particularly since it is the first test in GTR that is used
to identify the tissue in which a malignancy originates," said Wendy
Rubinstein, M.D., Ph.D., Director of the Genetic Testing Registry and Senior
Scientist at the National Center for Biotechnology Information, a division of
the National Library of Medicine at the National Institutes of Health. "Our
goal is to provide an efficient means for health care providers, researchers,
and others to access detailed information about the broad range of available
genetic and genomic tests.The addition of the Response Genetics menu of
genomic tests for cancer to our database will significantly further this
goal."

Information about the Response Genetics menu can now be found at:
http://www.ncbi.nlm.nih.gov/gtr/tests/512726/

To learn more about the GTR, visit http://www.ncbi.nlm.nih.gov/gtr/.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer.The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens.The Company's principal customers include
oncologists and pathologists.In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry.The Company's headquarters is located in Los Angeles,
California.For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and
uncertainties.Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions, such as the ability of the Company, to provide clinical testing
services to the medical community, to continue to strengthen and expand its
sales force, to continue to build its digital pathology initiative, to attract
and retain qualified management, to continue to strengthen marketing
capabilities, to expand the suite of ResponseDX^® products, to continue to
provide clinical trial support to pharmaceutical clients, to enter into new
collaborations with pharmaceutical clients, to enter into areas of companion
diagnostics, to continue to execute on its business strategy and operations,
to continue to analyze cancer samples and the potential for using the results
of this research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, and other statements
identified by words such as "project," "may," "could," "would," "should,"
"believe," "expect," "anticipate," "estimate," "intend," "plan" or similar
expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities and
Exchange Commission.Actual results, including, without limitation, actual
sales results, if any, or the application of funds, may differ from those set
forth in the forward-looking statements.These forward-looking statements
involve certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company's control).The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973
        
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900

Response Genetics Logo
 
Press spacebar to pause and continue. Press esc to stop.